Senzime announces outcome in employee stock option program, issues 600 000 shares and receives a total of approximately SEK 5.3 million
Press release: Uppsala, November 26, 2020. Senzime AB (publ) announces today that all outstanding employee stock options within the Employee Stock Option Program 2017/2020 (the “Stock Option Program”) and related warrants have been exercised for subscription of shares.
All 600,000 options in the program have been exercised for subscription of shares and the Company has thus issued 600,000 new shares to the option holders at a price of SEK 8.80 per new share. The Company has thereby received approximately SEK 5.3 million.
After exercise of the options, the total number of outstanding employee stock options (with underlying warrants) in the Company amounts to 1,200,000 and the number of other outstanding warrants in the Company to 400,000, which corresponds to a total of 2.8 percent of the total share capital upon full dilution (if all shares attributable until the options are delivered).
After registration of the issue, the number of shares amounts to 57,948,290.
Senzime develops and markets systems, driven by unique algorithms and sensors, to follow patients ' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on November 26, 2020, 11:45 CET.
Explore our patient monitoring solutions
Get product details
How can Senzime’s products help to eliminate in-hospital complications?
Contact us to discuss your needs or schedule a product demo.